Qiagen stock weighs stronger Q3 margins against suspended outlook

QIAGEN reported stronger third-quarter profitability on Wednesday, November 4, while suspending its full-year outlook because of the pending transaction with EQT Private Equity. The company's investor-relations release said sales and adjusted diluted earnings per share exceeded its outlook.

Sales and mix support growth

Third-quarter net sales rose 3 percent year over year to 548 million US dollars. Growth also reached 3 percent at constant exchange rates, above the company's outlook for 1 to 2 percent constant-currency growth. Consumables and related revenues increased 3 percent at constant exchange rates and represented 91 percent of sales. Instrument revenue rose 1 percent, while QIAGEN's growth pillars increased 7 percent at constant exchange rates to 415 million US dollars. The rest of the portfolio declined 7 percent on the same basis.

QIAGEN's Investor Relations release said reported operating income rose to 132 million US dollars from 129 million US dollars. Adjusted operating income increased 6 percent to 167 million US dollars, lifting the adjusted operating margin to 30.4 percent from 29.6 percent.

Adjusted results improve, outlook stays suspended

QIAGEN attributed the margin improvement to sales growth, a larger contribution from higher-margin consumables and efficiency gains. The company also continued investing in Parse Biosciences after its late-2025 acquisition. Reported diluted earnings per share fell to 0.51 US dollars from 0.60 US dollars, while adjusted diluted earnings per share rose to 0.65 US dollars from 0.61 US dollars and exceeded the outlook of at least 0.62 US dollars at constant exchange rates.

Operating cash flow reached 447 million US dollars in the first nine months of 2026, compared with 466 million US dollars in the prior-year period. The adjusted figures provide a clearer view of operating momentum, but they are non-GAAP measures and do not replace reported earnings.

QIAGEN will not provide financial guidance while the proposed EQT transaction remains pending. The tender offer has not yet commenced, leaving regulatory progress and the transaction timetable as important near-term factors for shareholders.

Qiagen stock traded at 45.17 euros on Lang & Schwarz at 18:04 CET on Tuesday, November 10, 2026, 0.13 percent below the Xetra close of 45.23 euros on Tuesday, November 10.

The Dutch market backdrop remains relevant through the AEX market.

Further developments on the transaction, including the start of the tender offer and regulatory progress, are likely to remain central for investors following more news and analyses on Qiagen stock.